Dr. Diasio became the Director of Mayo Clinic Cancer Center (MCCC) on September 1, 2006. He was selected for this position in May 2006 after a national search that resulted in his moving to Mayo Clinic from the University of Alabama at Birmingham where he had been on the faculty for 22 years, including being an active member of the University of Alabama at Birmingham Comprehensive Cancer Center. At University of Alabama at Birmingham, he had held several Cancer Center leadership positions (initially Program Leader of Cancer Pharmacology and subsequently Program Leader of a much larger Program in Experimental Therapeutics, and still later Associate Director for Basic Sciences, with responsibility for oversight of basic science programs and shared resources). He was active on the University of Alabama at Birmingham faculty as both a medical oncologist and pharrhacologist, and held several leadership positions as detailed below. Dr. Diasio is the fourth director of MCCC. At Mayo Clinic he also holds the position of William J. and Charles H. Mayo Professor, as well as Consultant and Professor in the Department of Molecular Pharmacology &Experimental Therapeutics and the Department of Oncology

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682960
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$199,577
Indirect Cost
$74,165
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Zhou, Dan; Hlady, Ryan A; Schafer, Marissa J et al. (2017) High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver. Epigenetics 12:55-69
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393

Showing the most recent 10 out of 1086 publications